Is There a Chemo-Free Approach for Early-Stage NSCLC?

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Integrating Immune Checkpoint Therapy into Early-Stage Non-Small Cell Lung Cancer

Is There a Chemo-Free Approach for Early-Stage NSCLC?

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
2.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    This program discusses the expanding use of ICIs to treat patients with early-stage NSCLC. The education addresses newly approved and investigational perioperative neoadjuvant and adjuvant therapy with ICIs. It includes scientific rationale driving research, clinical trial surrogate endpoints, identification of predictive biomarkers, mechanisms of disease resistance, efficacy and safety data from recent pivotal clinical trials, and clinical management challenges. 

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including oncologists, pathologists, surgeons, oncology nurses, and pharmacists, as well as other clinicians involved in the management of patients with Non-Small Cell Lung Cancer (NSCLC).

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify patients with early-stage NSCLC who may benefit from treatment with neoadjuvant and adjuvant ICIs
    • Describe the surrogate endpoints being used in clinical trials to assess efficacy in perioperative treatment with neoadjuvant and adjuvant ICIs
    • Discuss the biomarkers used in research and practice for predicting response to ICIs in perioperative neoadjuvant and adjuvant settings
    • Apply data from clinical trials of ICIs in neoadjuvant and adjuvant settings to inform treatment strategies for early-stage NSCLC
    • Identify strategies for managing risks and complications of toxicities and other potential complications (e.g., pseudoprogression and hyperprogression) in these settings.
    • Recognize the outstanding issues with regard to optimal dose, timing, and schedule
  • Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 2.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Tricia Cottrell, MD, PhD, faculty for this educational event, received consulting fees from AstraZeneca.

    Patrick Forde, MBBCH, faculty for this educational event, received research funding from AstraZeneca, BioNTech, BMS, Novartis, and Regeneron; and received consulting fees from Amgen, AstraZeneca, BMS, Daiichi, F-Star, G1, Genentech, Janssen, Iteos, Merck, Sanofi, Novartis, and Surface; and served on a Data & Safety Monitoring Board for Polaris. 

    Solange Peters, MD, PhD, faculty for this educational event, is principal investigator in trials sponsored by Amgen, AstraZeneca, Beigene, Bristol-Myers Squibb, GSK, Merck Sharp and Dohme, and Roche/Genentech; and has received consulting fees from AbbVie, AiCME, Amgen, Arcus, AstraZeneca, Bayer, Beigene, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GSK, Illumina, Imedex, IQVIA, Incyte, Ipsen, iTeos, Janssen, Medscape, Medtoday, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Novartis, Novocure, OncologyEducation, Pharma Mar, Phosplatin Therapeutics, PER, Peerview, Pfizer, PRIME, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda, and Vaccibody.

    Jonathan D. Spicer, MD, PhD, FRCSC, faculty for this educational event, has received research funding from Merck (MSD), Roche, BMS, AZ,
    Protalix Biotherapeutics, and CLS Therapeutics; and received consulting fees from Merck (MSD), BMS, AstraZeneca, Roche, Amgen, Chemocentryx, and Novartis.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by independent educational grants from Merck Sharp & Dohme LLC, Genentech (a member of the Roche Group), and Bristol Myers Squibb.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 11/30/2022 through 11/30/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%.
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule2 Oct 2023